CA2590751A1 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling - Google Patents

Polynucleotides and polypeptide sequences involved in the process of bone remodeling Download PDF

Info

Publication number
CA2590751A1
CA2590751A1 CA002590751A CA2590751A CA2590751A1 CA 2590751 A1 CA2590751 A1 CA 2590751A1 CA 002590751 A CA002590751 A CA 002590751A CA 2590751 A CA2590751 A CA 2590751A CA 2590751 A1 CA2590751 A1 CA 2590751A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
polynucleotide
sequence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002590751A
Other languages
English (en)
French (fr)
Inventor
Roy Rabindranauth Sooknanan
Gilles Bernard Tremblay
Mario Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alethia Biotherapeutics ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2590751A1 publication Critical patent/CA2590751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
CA002590751A 2004-12-13 2005-12-13 Polynucleotides and polypeptide sequences involved in the process of bone remodeling Abandoned CA2590751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63498104P 2004-12-13 2004-12-13
US60/634,981 2004-12-13
PCT/CA2005/001917 WO2006063462A1 (en) 2004-12-13 2005-12-13 Polynucleotides and polypeptide sequences involved in the process of bone remodeling

Publications (1)

Publication Number Publication Date
CA2590751A1 true CA2590751A1 (en) 2006-06-22

Family

ID=36587499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002590751A Abandoned CA2590751A1 (en) 2004-12-13 2005-12-13 Polynucleotides and polypeptide sequences involved in the process of bone remodeling

Country Status (6)

Country Link
US (3) US7947436B2 (enExample)
EP (2) EP1831370A4 (enExample)
JP (1) JP2008522632A (enExample)
AU (1) AU2005316169B2 (enExample)
CA (1) CA2590751A1 (enExample)
WO (1) WO2006063462A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173838B2 (ja) † 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5451376B2 (ja) * 2007-03-15 2014-03-26 株式会社リバース・プロテオミクス研究所 血球系に特異的あるいは破骨細胞分化に特異的なバイオマーカー
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
KR101463325B1 (ko) * 2013-01-14 2014-11-20 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
JP2014230493A (ja) * 2013-05-28 2014-12-11 三菱レイヨン株式会社 間葉系幹細胞からの分化状態を識別する遺伝子群及び分化状態の評価方法
CN111836635A (zh) 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037640A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Compositions and methods for the treatment of tumor
KR100202640B1 (ko) * 1995-12-07 1999-06-15 구본준 씨알티의 잔류자속 제거방법
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US5871917A (en) * 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US5968782A (en) 1996-12-04 1999-10-19 Brigham And Womens's Hospital, Inc. Mast cell protease that cleaves fibrinogen
US6479274B1 (en) * 1997-02-13 2002-11-12 Amrad Operations Pty., Ltd. DNA molecules encoding human HELA2 or testisin serine proteinases
WO2001036440A1 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 23 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7193048B2 (en) 1997-03-31 2007-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6203979B1 (en) * 1998-01-16 2001-03-20 Incyte Pharmaceuticals, Inc. Human protease molecules
US7022821B1 (en) 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
WO1999057144A2 (en) 1998-05-05 1999-11-11 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules
US6998260B1 (en) 1998-05-15 2006-02-14 Promega Corporation Recombinant proteolytic tryptases, active site mutants thereof, and methods of making same
WO2000029448A2 (en) 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
US20050053983A1 (en) * 1998-11-20 2005-03-10 Fuso Pharmaceutical Industries, Ltd. Novel serine protease BSSP4
EP1132477A4 (en) 1998-11-20 2003-05-07 Fuso Pharmaceutical Ind SERINE PROTEASE BSSP4
EP1161266A4 (en) 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications
WO2001023547A1 (en) 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 26 human secreted proteins
US20070048818A1 (en) 1999-03-12 2007-03-01 Human Genome Sciences, Inc. Human secreted proteins
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US6485957B1 (en) * 1999-04-30 2002-11-26 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding the human serine protease EOS
US6420157B1 (en) * 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
CA2379925A1 (en) * 1999-07-20 2001-01-25 Curagen Corporation Polypeptides and polynucleotides encoding same
US20030207348A1 (en) * 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
CA2379652A1 (en) 1999-08-18 2001-02-22 Zymogenetics, Inc. Tryptase-like polypeptide ztryp1
US6514741B1 (en) * 1999-08-18 2003-02-04 Zymogenetics, Inc. Tryptase-like polypeptide ztryp1
US6426199B1 (en) * 1999-08-31 2002-07-30 Ortho-Mcneil Pharmaceutical, Inc. Dna
US6458564B1 (en) * 1999-08-31 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding the human serine protease T
EP1087230A1 (en) * 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Method for identifying compounds useful in the therapy of bone disorders
US20060084054A1 (en) 1999-09-27 2006-04-20 John Alsobrook Novel proteins and nucleic acids encoding same
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
AU1205901A (en) * 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
WO2001036645A2 (en) 1999-11-17 2001-05-25 Curagen Corporation Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2001046443A2 (en) 1999-12-23 2001-06-28 Incyte Genomics, Inc. Proteases
US20030050231A1 (en) 2000-01-31 2003-03-13 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020042386A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20040043930A1 (en) * 2000-02-08 2004-03-04 Anderson David W. Novel proteins and nucleic acids encoding same
EP1255833A2 (en) 2000-02-15 2002-11-13 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001066747A2 (en) 2000-03-03 2001-09-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001283872A1 (en) * 2000-06-21 2002-01-02 Bayer Aktiengesellschaft Regulation of human eosinophil serine protease 1-like enzyme
US7049420B2 (en) * 2000-06-23 2006-05-23 Bayer Healthcare Ag Regulation of human prostasin-like serine protease
WO2001098467A2 (en) 2000-06-23 2001-12-27 Bayer Aktiengesellschaft Regulation of human prostasin-like serine protease
AU2001271427A1 (en) * 2000-06-26 2002-01-08 Sugen, Inc. Novel proteases
US20030077647A1 (en) * 2001-10-09 2003-04-24 Millennium Pharmaceuticals, Inc. 14081, a human trypsin-like serine protease family member and uses therefor
US20020045230A1 (en) 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
JPWO2002027502A1 (ja) * 2000-09-26 2004-02-05 株式会社東芝 電子メールの送受信プログラムを記録した記録媒体
AU2002241570A1 (en) 2000-10-24 2002-06-18 Curagen Corporation Human proteins, polynucleotides encoding them and methods of using the same
WO2002059315A2 (en) 2000-12-19 2002-08-01 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
WO2002055704A2 (en) 2001-01-09 2002-07-18 Curagen Corp Proteins, polynucleotides encoding them and methods of using the same
WO2002068647A2 (en) 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
WO2002098917A2 (en) 2001-02-12 2002-12-12 Curagen Corporation Human proteins and nucleic acids encoding same
CA2438433A1 (en) 2001-02-14 2002-08-22 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US6482630B2 (en) * 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US20060188903A1 (en) * 2001-04-06 2006-08-24 Rancourt Derrick E Implantation serine proteinases
JP2004535169A (ja) 2001-04-06 2004-11-25 ランコート，デリック，イー． 着床セリンプロテアーゼ
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2002324451A1 (en) 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
WO2003063688A2 (en) 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
EP1471818A4 (en) 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
JP2003334094A (ja) * 2002-03-15 2003-11-25 Sankyo Co Ltd 骨代謝異常の治療または予防剤の試験方法
US7160994B2 (en) * 2002-03-28 2007-01-09 Trustees Of The University Of Pennsylvania Osteoclast-specific genes and proteins and uses thereof
EP1792912A3 (en) 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20030124706A1 (en) * 2002-06-21 2003-07-03 Junming Yang Proteases
WO2004009803A2 (en) 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation of human hepsin
US6977170B2 (en) * 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2006507813A (ja) 2002-10-04 2006-03-09 シエーリング アクチエンゲゼルシャフト 置換体活性化配列を有する修飾されたヘプシン分子及びその使用
AU2003279829A1 (en) 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2002951912A0 (en) 2002-10-08 2002-10-24 Unisearch Limited Tryptase polypeptide and uses thereof
AU2003295511A1 (en) 2002-11-13 2004-06-03 Genentech, Inc. Methods and compositions for diagnosing dysplasia
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053068A2 (en) 2002-12-05 2004-06-24 Incyte Corporation Protein modification and maintenance molecules
EP2474630B1 (en) * 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2004086035A1 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepsin (hpn)
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1633850A4 (en) 2003-05-16 2007-04-04 Diadexus Inc OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
WO2004106536A2 (en) 2003-05-28 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serine protease 8 (prss8)
CN1833020A (zh) 2003-06-27 2006-09-13 迪亚德克瑟斯公司 Pro104抗体组合物及其使用方法
WO2005005647A2 (en) 2003-06-30 2005-01-20 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US20040137623A1 (en) * 2003-09-17 2004-07-15 Isis Pharmaceuticals, Inc. Delivery of oligonucleotide compounds into osteoclasts and modulation of osteoclast differentiation
US20050176030A1 (en) * 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
EP1711622A2 (en) * 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20050153333A1 (en) * 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1774046A4 (en) 2004-01-27 2010-09-15 Compugen Usa Inc NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND ASSAYS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF LUNG CANCER
US7569662B2 (en) 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US20060084066A1 (en) * 2004-02-20 2006-04-20 Sah Dinah W Y Surrogate markers of neuropathic pain
WO2005119262A2 (en) 2004-05-27 2005-12-15 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
KR101222254B1 (ko) 2004-07-26 2013-01-16 제넨테크, 인크. 간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
WO2006013016A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
WO2006013015A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with marapsin (mpn)
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
KR101126423B1 (ko) * 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7510850B2 (en) 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
WO2007140907A1 (en) 2006-06-07 2007-12-13 Bayer Healthcare Ag Use of serine endopeptidases 22 (prss22) as a therapeutic or diagnostic target
CN101490088B (zh) 2006-06-22 2015-04-08 健泰科生物技术公司 用于靶向hepsin的方法和组合物
US20100061996A1 (en) 2006-06-22 2010-03-11 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
EP2052088A2 (en) * 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CA2670107A1 (en) * 2006-11-22 2008-06-05 The Board Of Trustees Of The University Of Arkansas Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer

Also Published As

Publication number Publication date
US20110293604A1 (en) 2011-12-01
EP1831370A4 (en) 2009-08-12
US20120308561A1 (en) 2012-12-06
US7947436B2 (en) 2011-05-24
WO2006063462A9 (en) 2007-07-26
EP2275547A3 (en) 2011-05-04
JP2008522632A (ja) 2008-07-03
WO2006063462A1 (en) 2006-06-22
US8444975B2 (en) 2013-05-21
EP2275547A2 (en) 2011-01-19
EP2275547B1 (en) 2014-03-05
US20090004206A1 (en) 2009-01-01
AU2005316169A1 (en) 2006-06-22
EP1831370A1 (en) 2007-09-12
AU2005316169B2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
USRE47672E1 (en) Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8540988B2 (en) Antibodies that bind polypeptides involved in the process of bone remodeling
CA2655933A1 (en) Polynucleotides and polypeptide sequences involved in cancer
US8444975B2 (en) Method for inhibiting bone resorption
AU2014200123B2 (en) Polynucleotides and polypeptide sequences involved in the process of bone remodeling
WO2005035716A2 (en) Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131213